Evidence map›Paper›PMID 28941213›Full record

ArticleAutism research : official journal of the International Society for Autism Research2018

Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.

C H Chatham, K I Taylor, T Charman, X Liogier D'ardhuy, E Eule, A Fedele, A Y Hardan, E Loth, L Murtagh, M Del Valle Rubido and 10 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Autism research : official journal of the International Society for Autism Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 90 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04089579 phase2completednot on this mapstarted 2020, after this paper: background citation

A Phase II Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder

TypeinterventionalSponsorJoanne Kurtzberg, MDRan2020 to 2024Enrolled137ConditionsAutism, Autism Spectrum DisorderArmsCord Tissue Mesenchymal Stromal Cells, Placebo Infusion
NCT05750095 narecruitingnot on this mapstarted 2022, after this paper: background citation

Enabling Parents of Children With Autism Spectrum Disorders - a Randomized Controlled Trial of Parenting Programs

TypeinterventionalSponsorHaukeland University HospitalRan2022 to 2028Enrolled240ConditionsAutism Spectrum DisorderArmsIncredible Years Autism Spectrum and Language Delay Programme, First Aid for Parents
NCT06596226 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluating The Efficacy of Pathways Parent-Mediated Intervention's Mutual Gaze Protocol on Social Skills in Young Children Suspected of Having Autism: A Randomized Control Trial

TypeinterventionalSponsorThe University of Texas at DallasRan2024 to 2026Enrolled80ConditionsAutismArmsPathways Parent Mediated Intervention, Pathways Parent Mediated Intervention without Mutual Gaze
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Eye Tracking as a Treatment Monitoring Tool for Autism: A Multilevel Meta-Analysis.Autism research : official journal of the International Society for Autism Research · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Caregiver Meaningful Score Differences and Meaningful Score Regions for the Observer-Reported Communication Ability Measure for Individuals with Angelman Syndrome.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Parental Stress and Caregiver Role Modulate Child-Caregiver Prosodic Synchrony in Autism: A Computational Analysis.Autism research : official journal of the International Society for Autism Research · 2026
    Article
  18. Review
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

C H ChathamF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.ORCID 0000-0003-4427-8285
K I TaylorF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
T CharmanInstitute of Psychiatry, Psychology & Neuroscience, King's College London, Camberwell, London, SE5 8AF, UK.
X Liogier D'ardhuyF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
E EuleF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
A FedeleAutism Speaks, New York, New York, 10016.
A Y HardanPsychiatry and Behavioral Sciences, Stanford University, Stanford, California, 94305-5717.
E LothInstitute of Psychiatry, Psychology & Neuroscience, King's College London, Camberwell, London, SE5 8AF, UK.
L MurtaghF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
M Del Valle RubidoF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.ORCID 0000-0001-5912-1788
A San Jose CaceresInstitute of Psychiatry, Psychology & Neuroscience, King's College London, Camberwell, London, SE5 8AF, UK.
J SevignyF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
L SikichDuke Center for Autism and Brain Development, Pavilion East at Lakeview, Durham, North Carolina, 27705.
L SnyderSimons Foundation, New York, New York, 10010.
J E TillmannInstitute of Psychiatry, Psychology & Neuroscience, King's College London, Camberwell, London, SE5 8AF, UK.
P E VentolaYale Child Study Center, New Haven, CT, 06520.
K L Walton-BowenSimons Foundation, New York, New York, 10010.
P P WangSimons Foundation, New York, New York, 10010.
T WillgossF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.
F BolognaniF. Hoffmann La Roche, Innovation Center Basel, Hoffmann La Roche, Basel, 4070, Switzerland.

Funding

Translational Developmental Neuroscience of AutismK23MH087770 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DI MARTINO, ADRIANA · 2010 to 2013
$644k
Enhancing the Autism Brain Imaging Data Exchange to Define the Autism ConnectomeR21MH107045 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DI MARTINO, ADRIANA · 2015 to 2016
$479k
Autism Speaks AS1280NIMH NIH HHS K23 MH087770NIMH NIH HHS R21 MH107045
6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland-II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU-AIMS LEAP study, ABIDE-I, ABIDE-II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution-based methods and anchor-based methods. Distribution-based MCID [d-MCID] estimates included the standard error of the measurement, as well as one-fifth and one-half of the covariate-adjusted standard deviation (both cross-sectionally and longitudinally). Anchor-based MCID [a-MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland-II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland-II change, the Vineland-II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland-II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution-based methods, and from 2.42 to 3.75 for sample-size-weighted anchor-based methods. Lower Vineland-II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland-II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270-283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: The Vineland Adaptive Behavior Scales (2nd edition; Vineland-II) is the most widely used scale for assessing day-to-day "adaptive" skills. Yet, it is unknown how much Vineland-II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2-3.75 points on the Vineland-II Composite score represent the "minimal clinically-important difference." These estimates will help evaluate the benefits of potential new treatments for ASD.

Indexed as

Adaptation, PsychologicalMinimal Clinically Important DifferenceActivities of Daily LivingAdolescentAdultAutism Spectrum DisorderChildChild, PreschoolCommunicationFemaleHumansInfantMaleMiddle AgedModels, PsychologicalMotor Skillsassessmentautism spectrum disorderefficacyintellectual disabilityintelligencetreatmentVABS

Identifiers

PMID28941213
PMCPMC5997920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.